We have utilized a number of well-defined, simple, synthetic promoters (upstream factor binding sites and TATA elements) to analyze the activation mechanisms of the human cytomegalovirus immediate-early (IE) proteins. We found that the 86-kDa IE protein (known as IEP86, IE2,g5aa, or 67:7539-7546, 1993) but also with its ability to interact with the transcription factors which bind to the upstream element of promoters it activated (e.g., SP1 and Tef-1 but not Oct-i). This ability to have multiple interactions with the promoter complex may be crucial for transcriptional activation, since the IE proteins cannot activate promoters having only a TATA element or only an upstream transcription factor binding site. In addition, we show that proteins which bind IEP86 also bind to IEP55. Thus, the negative effect on transcription noted with IEP55 may be the result of competition with IEP86 for interaction with the promoter complex. The synergy caused by IEP72 appears to be mediated by a more indirect mechanism. This is suggested by our observation that IEP72 could not bind to any of the proteins tested (TBP, Tef-1, or Oct-1) or to IEP86.
Oct-i). This ability to have multiple interactions with the promoter complex may be crucial for transcriptional activation, since the IE proteins cannot activate promoters having only a TATA element or only an upstream transcription factor binding site. In addition, we show that proteins which bind IEP86 also bind to IEP55. Thus, the negative effect on transcription noted with IEP55 may be the result of competition with IEP86 for interaction with the promoter complex. The synergy caused by IEP72 appears to be mediated by a more indirect mechanism. This is suggested by our observation that IEP72 could not bind to any of the proteins tested (TBP, Tef-1, or Oct-1) or to IEP86.
The human cytomegalovirus (HCMV) major immediateearly promoter (MIEP) controls the expression of a primary transcript that is alternately spliced and polyadenylated to form mRNAs encoding several different immediate-early (IE) gene products (Fig. 1 ). These include a set of proteins traditionally designated IEl and IE2, which denote the two major coding areas within the total IE region (Fig. 1 ). However, due to the alternate splicing, these areas are capable of encoding several proteins (49) . The major product of the IEl region is a 72-kDa protein, hereafter termed IEP72. The IE2 region, or parts of it, are found in several alternately spliced transcripts (49) . One of these transcripts produces an 86-kDa protein; another potentially encodes a 55-kDa protein (22, 35, 46, 48) . Hereafter, these will be termed IEP86 and IEP55, respectively.
The role of these proteins as modulators of transcription from both cellular and viral promoters has been examined in many reports. However, the results of these studies are quite varied. This may largely be a consequence of the use of several different cell types in these experiments, as well as a number of different test promoters. Hence, the variations in transcriptional effects may suggest cell type differences in the response to, or utilization of, the IE proteins. In a broad overview of the literature, it is often observed that IEP86 (or the IE2 product) is a promiscuous transcriptional activator (5, 10, 11, 15, 20, 21, 29, 32-34, 36, 37, 53, 55, 59, 60) . However, a few experiments have shown some promoters and/or cell types in which IEP86 failed to activate whereas IEP72 (the IEl product) caused activation (3, 6, 8, 12, 20, 23, 33, 47) . In addition, instances in which both proteins activated the same promoters independently have been reported (5, 10, 15, 20, 21, 29, 32, 33, 55, 60) . Still other reports have indicated that a combination of the IEl and IE2 gene products is capable of activating both viral and cellular promoters (13, 24, 39, 44, 45, 54) . There is somewhat more agreement when IEP86 and IEP72 are supplied together: activation is at least additive and most often synergistic (10, 12, 15, 29, 33, 34, 47, 53) . Synergy is often reported in cases where the test promoter is activated by IEP86 and not IEP72, when tested individually.
Less is known about IEP55, a splice variant of IEP86 ( Fig.  1) . It is generally observed that IEP55 expression will decrease the level of activation seen with IEP86 and IEP72 (15, 29, 47 The structure of IEP55 and its effect provide the attractive possibility that IEP55 acts in a manner similar to that of other transcription-repressing viral proteins that are alternatively spliced gene products of the proteins that they inhibit (for example, the adenovirus Ela 12S RNA product [31] ). However, it is not clear whether IEP55 is expressed with other IE proteins during infection. Although its 1.7-kb mRNA is detectable during the IE period, the corresponding protein has been seen only after cycloheximide treatment of the infected cells (22, 35, 46, 48) . Hence, the significance of its effect in viral infection remains speculative.
Overall, the above data suggest a pattern of activation by the individual IEP72 and IEP86 proteins that varies with conditions and promoters. Layered on this is the complexity that the effects of the individual IEP72 and IEP86 proteins can be synergistic in combination and can be downregulated by IE55. The observations (i) that IEP86 prefers specific TATA elements (4, 5, 15, 20, 21, 55) and (ii) that IEP86 can interact with the TATA-binding protein (TBP), and possibly other proteins (14, 20, 26) , suggest that direct interaction with multiple components of the transcription complex may be a means of transcriptional activation.
In The ability of IEP86 to activate many simple promoters and its ability to interact with TBP (14, 20, 26) are similar to our previous observations of transcriptional activation by simian virus 40 (SV40) large T antigen (16, 18, 19, 40) . Specifically, T antigen activates many simple promoters and it interacts with TBP. In addition, T antigen has been shown to interact with the factors which bind to upstream promoter elements (19) . Hence, there are multiple interactions with the promoter complex which appear to affect transcription through stabilization of the transcription complex (19) . We (Fig. 1 ). This plasmid can potentially produce all spliced and polyadenylated forms of the IE mRNAs; hence, it can potentially express IEP55, IEP72, and IEP86 (36) . pCMVTAg is a plasmid in which the SV40 large T antigen is driven by the cytomegalovirus (CMV) MIEP (19) . Plasmid pMSVP16 (a gift of S. McKnight) expresses the herpes simplex virus type 1 tegument transcriptional activator VP16, under the control of the murine sarcoma virus LTR.
Several plasmids contained specific promoters with attached reporter genes and were used as reporters for the effects of IE proteins on promoter activity. Among the reporter plasmids listed below, some were based on the chloramphenicol acetyltransferase (CAT) reporter gene and others were based on the 3-globin reporter gene.
A group of related simple promoter constructions based on the hsp70 gene promoter were the gift of R. Kingston and have been described elsewhere (52) . Briefly, each contains human hsp70 gene promoter sequences, from position -84 relative to the transcription start site, adjacent to the CAT gene (Fig. 2) (43) .
Plasmids pp6xB20 and its mutant derivatives dpm 2 (Sph-), dpm 7 (Oct-), and dpm 8 (Oct-Sph-) contain six tandem copies of the wild-type or mutant SV40 late promoter region between bases 200 to 219, upstream of the human 3-globin TATA box and gene, as previously described (51) . All of these plasmids express ,-globin mRNA as the reporter gene product. Plasmid pSP6,B350 (51) was used to generate the antisense 3-globin RNA used to detect 3-globin mRNA in RNase protection assays (described below).
Fusions of the HCMV IE proteins were made with the glutathione binding site of glutathione S-transferase (GST). These GST fusion plasmids are pGEX-3xIE55, pGEX-3xIE72, and pGEX-3xIE86, encoding the fusions with IEP55, IEP72, and IEP86, respectively. They were constructed by PCR subcloning, with the pIE series of plasmids (described above) as templates. The PCR primers introduced single 5' and 3' terminal restriction sites (BamHI and EcoRI, respectively) to the coding region of each full-length CMV cDNA to allow in-frame insertion into the plasmid pGEX-3X (Pharmacia). The sequences of the primers used (with restriction sites underlined and a base changed from the IE protein sequences in bold) were as follows: 5' primer for pGEX3x-IE55, -IE72, and -IE86, CGCGGATCCTGGAGTCCTCTGCC; 3' primer for GEX3x-IE55 and -IE86, CGCGAAIT[CTGAGAC'TT7GT TCCTC; and 3' primer for GEX3x-IE72, CGCGAATTCTG GTCAGCCTTGCTTCC.
Several plasmids were utilized for the in vitro transcription and translation of various proteins. Plasmid pETHIID directs the synthesis of human TBP and was a gift from Arnold Berk (27) . Plasmid pXJ40Tef1A directs the synthesis of human Tef-1 protein and was a gift from Pierre Chambon (57). pBS-Oct 1 directs the synthesis of human Oct-1 protein (50). pBS-Spl-F1 directs the synthesis of the full-length Spl protein and was a gift of Robert Tjian.
Cell culture and transfection. The African green monkey kidney cell line CV-1 was propagated and maintained in Dulbecco's minimal essential medium supplemented with 5% fetal bovine serum at 37°C in 5% Co2. Low-passage cells were plated at approximately 6 x 105 cells per 100-mm-diameter plate for RNA analyses or 2 x 105 cells per 60-mm-diameter plate for CAT analyses and grown overnight. Monolayers at approximately 70% confluence were transfected with 12 ,ug of DNA for RNA analyses or 10 ,ug of DNA for CAT analyses (plasmid pXJ40 E/B [19, 57] was used as a filler to equalize, when necessary, the total DNA used per transfection). Transfections were done by the calcium phosphate precipitation procedure using the N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) modification (7). The calcium phosphate precipitate was left on the cells for 17 to 20 h, and the cells were then shocked with 15% glycerol (in BES-buffered saline) for 1 min before fresh medium was added. For RNA preparation, cells were harvested 24 h after glycerol shock, as described below. For CAT protein preparation, the cells were harvested 48 h after glycerol shock, as previously described (28) . Extract protein concentrations were determined by the Bradford method (Bio-Rad). It should be noted that although the presented experiments used CV-1 cells, many of the experiments discussed below have also been done with the human T-cell line Jurkat. The results of these experiments are essentially identical to the data obtained with CV-1. CV-1 cells are utilized because of their adherent nature and ease of transfection.
Many transfection studies are internally standardized for transfection variations through the use of a second reporter gene on an independent promoter. In the case of transcriptional activation analyses using IEP86, T antigen, and other viral activators, this is a somewhat ineffectual undertaking since these activators exert some level of activation on most promoters (1). We In activating these simple promoters, both Ela and T antigen show preferences for specific TATA elements (16, 40, 52) . (hsp7o TATA > adenovirus E2a TATA, with little activation from the SV40 early TATA or the nonsense element). Figure 3 shows the results of experiments to test TATA preference using the CMV IE proteins. SP1 was used as the USE with each TATA element, the initiator element, and no TATA (None). SP1 was chosen as the test USE because previous studies using these promoter constructions showed that an SP1 site was a USE preferred by SV40 T antigen (16, 40) . In addition, mutations of the SP1 sites in the human immunodeficiency virus LTR had significant effects on activation by the HCMV IE proteins (data not shown).
Plasmid pRIA3a, which is potentially able to produce all of the IE proteins (see Materials and Methods), was cotransfected into CV-1 cells along with the simple promoter reporter plasmids. As shown in Fig. 3 , the SPl/hsp7O and SP1/E2a promoters displayed 10-and 7-fold increases, respectively, in CAT activity over basal promoter levels (basal activities for these simple promoters are equivalent and given the arbitrary value of 1). However, the SP1/SV40E, SPl/initiator, and SPl/nonsense constructs displayed no significant activation over their basal activities. In the case of the initiator, the inability to activate is not due to a failure of the SPl/initiator promoter to function since SV40 T antigen can activate this promoter (16) .
To determine the effect of varying the USE on transcriptional activation by the CMV IE proteins, pRL43a was cotransfected with the simple promoter reporter plasmids in which various USEs, or the nonsense sequence, were linked to the hsp7o TATA (Fig. 2) . The hsp70 TATA element was used because of its apparent preference in the preceding experiment. As shown in Fig. 4 (IE region panel) , expression of the IE region with CCAAT/hsp7O, SP1/hsp70, and ATF/hsp7o caused 14-, 9-, and 4-fold increases, respectively, in CAT Fig. 4, IEP86 panel) . Expression of IEP72 alone caused no activation (IEP72 panel). However, the addition of both IEP86 and IEP72 (IEP72 and IEP86 panel) produced a synergistic effect equivalent to an approximate 3.7-fold increase over the activity of each promoter in the presence of IEP86 alone. Even the promoters which showed little or no activation by IEP86 alone, APl/hsp70 and OCTA/hsp7O, had increased activity in the presence of IEP86 and IEP72. The effect of IEPSS was also determined in cotransfection experiments. IEPSS alone had no effect on promoter activity; however, for the promoters activated by IEP86 and synergized by IEP86 plus IEP72, the addition of IEP55 decreased activity by two-to sixfold, depending on the promoter (data not shown).
Overall, these results indicate that (i) a very simple promoter structure can be activated by the IEP86 protein, (ii) this activation is synergized by IEP72 and repressed by IEP55, (iii) both a TATA element and a USE are required for activation, and (iv) there is a specific preference for particular TATA elements and USEs; this preference is very similar to that seen with SV40 T antigen (16, 40 ; see also the section on analogies below).
A very important consideration regarding the above data comes from the suggestion that one function of IEP72 is the specific activation of the CMV MIEP (3, 8, 41, 47) . Some of the plasmids used in the experiments described herein expressed the IE proteins from this promoter. Hence, it was possible that the synergy noted with IEP72 and IEP86 was simply due to increased production of IEP86 due to activation of the CMV IE promoter. For this reason, we have repeated the experiments presented with vectors which express the IE proteins from different promoters (the RSV LTR and the SRcx promoter; see Materials and Methods). The overall trends in activation were identical regardless of the promoter expressing the IE proteins (data not shown). This is in agreement with previous results (15) , in which IE protein expression from the promoter of the RSV LTR resulted in synergistic activation of the human immunodeficiency virus type 1 LTR.
It should be noted that although the experiments presented were done with CV-1 cells, all of the experiments whose results are shown in Fig. 4 and some of the experiments discussed below have also been done in the human T-cell line Jurkat. The results of these experiments are essentially identical to the data obtained for CV-1 cells.
Analogies between activation by CMV IE proteins and SV40 T antigen. The spectrum of promoters activated by IEP86 and SV40 T antigen are quite similar. The preference for TATA elements is the same, whereas USE preferences, although similar, show characteristics unique to each protein (CMV: CAAT > SP1 > ATF and shows no activation with AP1 and OCT; T antigen: SP1 > ATF > AP1 and shows no activation with CAAT and OCT [16, 40] ). SV40 T antigen also prefers to utilize promoters containing Tef-1 sites (19) . For example, the USE in the SV40 late promoter (Fig. 5A ) needed for T antigen-mediated transcriptional activation is a region containing two Tef-1 elements overlapped by an octamer element, known as the Oct/Tef element (OTE; Fig. 5B ). Within the OTE, it is the Tef-1 sites which are required for activation by T antigen (19) . In addition, a simple promoter containing the ,-globin TATA element and six upstream OTE motifs (Fig.  5C , OTE-TATA promoter) is substantially activated by T antigen (19) . This activation was shown to be due to the ability of T antigen to make multiple contacts with the promoter complex through interactions with both the Tef-1 protein and factors of the basal transcription complex, most prominently TBP (19) . The CMV 86-kDa protein has previously been shown to interact with TBP (14, 20, 26) . This finding, coupled with the requirement for an upstream element to activate simple promoters, suggests that IEP86, like SV40 T antigen, may also be able to interact with multiple components of the transcription complex. To approach this question, we first determined that the IE proteins activated the SV40 late promoter driving the CAT gene in CV-1 cells: IEP86 alone activated (18-+ 3-fold), IEP72 alone produced a modest activation (3-+ 1-fold), and together IEP72 and IEP86 synergized in activation (68-+ 7-fold).
Knowing that the late promoter was activated, we next utilized the simple OTE-TATA promoter (Fig. SC) mine whether the IE proteins were activated through the Tef-1 sites similarly to T antigen. Figure 6 shows quantitative nuclease protection analysis of the ,-globin RNA produced in CV-1 cells from the OTE-TATA promoter or its mutants (Fig. 5B  and C) . The wild-type promoter alone (Fig. 6 , lane WT Basal) has a very low basal activity. However, cotransfection of pRL43a caused a marked increase in ,B-globin RNA (Fig. 6 , lane WT + IE). To differentiate between utilization of the Tef-1 sites and the OCT site within the OTE, mutant simple promoters (51) which were constructed identically except for specific point mutations which disrupt the function of either the OCT site (Oct-, -0), the Tef sites (Tef-, -T), or both (Oct-Tef-, -T,-O) (Fig. SB [51]) were used. Figure 6 shows that mutation of the Tef-1 sites eliminated 1-globin RNA production in the presence of the IE proteins (lane -T+IE). However, mutation of the OCT site did not affect ,-globin RNA production in the presence of the IE proteins (lane -O+IE). Mutation of each site, expectedly, resulted in no RNA production (lane -T, -O+IE). We used the herpes simplex virus transcriptional activator VP16 to ensure that the mutation of the Tef-1 sites did not affect the OCT element function and to show that the OCT mutations eliminated OCT function. Figure 6 shows that the Tef-minus promoter is activated by VP16 (lane -T+VP16), whereas the OCT-minus mutant promoter is not (lane -O+VP16). The doublet seen in some lanes has previously been shown to be a nuclease artifact and not the utilization of a new start site (19) (see Materials and Methods). These data show that the IE proteins can utilize a Tef-1 site but not an OCT site as a USE. This result is in agreement with the simple promoter data obtained by using the OCT/hsp70 TATA promoter (Fig. 4) .
In the gel in Fig. 7 , the OTE-TATA promoter reporter plasmid was cotransfected with the plasmids which produce the individual IE proteins. As we have seen in previous experiments, IEP86 stimulated ,3-globin RNA synthesis, IEP72 had no effect, and the combination of IEP72 and IEP86 had a synergistic effect on promoter activity. These data provide one more example of a simple promoter structure which is activated by the IE proteins and large T antigen.
IEP86 interacts not only with components of the basal transcription complex but also with the upstream bound factor. The simplicity and similarity of the promoters activated by IEP86 and SV40 large T antigen suggested that they may utilize a common mechanism for transcriptional activation. It has previously been shown that T antigen interacts with both components of the basal transcription complex and with the factors bound upstream (19 (14, 20, 26) and is a positive control for binding; Tef-1 and SP1 might be expected to bind IEP86, since promoters containing their binding sites were well activated ( Fig. 4 and 5) ; and Oct-1 may be expected not to bind IEP86, since promoters containing its binding site were not activated ( Fig. 4 and 5) . Figure 8A shows that the glutathione binding site alone (Gst) does not bind any of the proteins. In agreement with previous data, the Gst-IE86 fusion binds to TBP; we extend this observation by showing that Gst-IE55 also binds to TBP. In addition, the data show that both Gst-IE55 and Gst-IE86 bind to Tef-1 but not to Oct-1, in agreement with the above predictions based on the promoters affected by the IE proteins (previous data from this laboratory indicated that the Oct-1 protein made in these experiments can interact with appropriate proteins [19] ). In further agreement with the predictions, Fig. 8B shows that Gst-IE86 binds to SP1 in a manner similar to transcription factor YY1, previously shown to interact with SP1 (42) .
In Fig. 9 , the binding of IEP86 and IEP55 with TBP and Tef-1 was tested by washing the complexes in increasing salt concentrations. Binding with TBP is relatively stable up to 300 mM NaCl; however, a moderate amount of binding continues after a washing in 500 mM NaCl (especially in the case of IEP55). This indicates that the interaction is primarily ionic but may also have some nonionic nature. The binding of both proteins to Tef-1 is relatively unaffected by increasing the NaCl concentration, suggesting that the interaction is primarily nonionic.
Many of the binding experiments discussed above have been repeated with the status of the proteins reversed, e.g., a GST fusion with TBP or Tef-1 and an in vitro-transcribed and -translated IEP86. All of these data (not shown) agreed with the results presented above. We have also tested a Gst-IE72 The synergy caused by IEP72 is seen with all promoters activated by IEP86 alone. In fact, this effect of IEP72 appears to be tailored for IEP86. In a comparison of simple promoters activated by both IEP86 and SV40 T antigen, the synergy of activation by IEP72 occurred only with IEP86 and has never been observed with SV40 T antigen (data not shown).
The above data suggest intimate interactions between IEP86 and the factors bound to the elements of the simple promoters which it activates. We provide evidence that this is indeed possible. We verify the interaction of IEP86 with TBP (14, 20, 26) . However, we also show that IEP86 interacts with the transcription factors which bind to USEs of promoters it activates (e.g., Tef-1 and SP1) and does not interact with transcription factors which interact with USEs of promoters it is unable to activate (e.g., Oct-1). Overall, these data suggest that transcriptional activation by IEP86 is mediated through multiple interactions with the promoter complex, i.e., interactions with the basal transcription complex (e.g., TBP) and interactions with the upstream bound factors (e.g., Tef-1 and SP1). The requirement for both of these interactions is indicated by the fact that IEP86 activates neither a promoter containing only an hsp70 TATA element nor one which contains only an upstream factor binding site ( Fig. 3 and 4) .
Interactions between IEP86 and factors in the transcription complex indicate that HCMV has evolved a transcriptional activation mechanism which is shared by other DNA viruses. The early, IE, or transactivator proteins of the papovaviruses, adenoviruses, and other herpesviruses have been shown to act, at least in part, through protein-protein interactions with factors involved in transcription. However, evidence also suggests that IEP86 binds to specific DNA sequences within the HCMV MIEP. This interaction appears to negatively regulate the MIEP and provide an autoregulatory function (25, 30, 56) . This dual functioning of IEP86, seen by comparing DNA binding and protein-protein interactions, is similar to the known transcriptional effects of SV40 large T antigen. It has been well documented that T antigen autoregulates its own synthesis by binding to specific sequences within the SV40 early promoter (38) , whereas it activates transcription of many promoters through interactions with factors of the transcription complex (16, 18, 19, 40 (Fig. 1) may provide the ability to form an activation domain or a domain for yet other critical protein-protein interactions. This region of IEP86 has been shown to be important for dimerization and DNA binding to the MIEP (9, 14, 25, 56) . We speculate that the negative effect of IEP55 may be due to competition with IEP86 for binding to cellular proteins in the promoter complex.
Overall, our data provide a model for both positive and negative transcriptional control mechanisms mediated by IEP86 and IEP55, respectively. This model can account for the promiscuous activation of promoters by IEP86. However, under our experimental conditions, the mechanism of synergy mediated by IEP72 remains unknown. The lack of evidence for direct interactions between IEP72 and other transcription factors, or with IEP86, suggests a more indirect means of action.
